dc.contributor.author | Fuchs, CS | |
dc.contributor.author | Tabernero, J | |
dc.contributor.author | Tomášek, J | |
dc.contributor.author | Chau, I | |
dc.contributor.author | Melichar, B | |
dc.contributor.author | Safran, H | |
dc.contributor.author | Tehfe, MA | |
dc.contributor.author | Filip, D | |
dc.contributor.author | Topuzov, E | |
dc.contributor.author | Schlittler, L | |
dc.contributor.author | Udrea, AA | |
dc.contributor.author | Campbell, W | |
dc.contributor.author | Brincat, S | |
dc.contributor.author | Emig, M | |
dc.contributor.author | Melemed, SA | |
dc.contributor.author | Hozak, RR | |
dc.contributor.author | Ferry, D | |
dc.contributor.author | Caldwell, CW | |
dc.contributor.author | Ajani, JA | |
dc.date.accessioned | 2017-04-03T09:34:57Z | |
dc.date.issued | 2016-10 | |
dc.identifier.citation | British journal of cancer, 2016, 115 (8), pp. 974 - 982 | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/539 | |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.doi | 10.1038/bjc.2016.293 | |
dc.description.abstract | Background Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. To attempt to identify prognostic and predictive biomarkers, retrospective analyses were used to assess tumour (HER2, VEGFR2) and serum (VEGF-C and -D, and soluble (s) VEGFR1 and 3) biomarkers in phase 3 REGARD patients with metastatic gastric/gastroesophageal junction carcinoma.Methods A total of 152 out of 355 (43%) patients randomised to ramucirumab or placebo had ⩾1 evaluable biomarker result using VEGFR2 immunohistochemistry or HER2, immunohistochemistry or FISH, of blinded baseline tumour tissue samples. Serum samples (32 patients, 9%) were assayed for VEGF-C and -D, and sVEGFR1 and 3.Results None of the biomarkers tested were associated with ramucirumab efficacy at a level of statistical significance. High VEGFR2 endothelial expression was associated with a non-significant prognostic trend toward shorter progression-free survival (high vs low HR=1.65, 95% CI=0.84,3.23). Treatment with ramucirumab was associated with a trend toward improved survival in both high (HR=0.69, 95% CI=0.38, 1.22) and low (HR=0.73, 95% CI=0.42, 1.26) VEGFR2 subgroups. The benefit associated with ramucirumab did not appear to differ by tumoural HER2 expression.Conclusions REGARD exploratory analyses did not identify a strong potentially predictive biomarker of ramucirumab efficacy; however, statistical power was limited. | |
dc.format | Print-Electronic | |
dc.format.extent | 974 - 982 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Esophagogastric Junction | |
dc.subject | Humans | |
dc.subject | Adenocarcinoma | |
dc.subject | Stomach Neoplasms | |
dc.subject | Receptor, erbB-2 | |
dc.subject | Receptors, Vascular Endothelial Growth Factor | |
dc.subject | Vascular Endothelial Growth Factor Receptor-2 | |
dc.subject | Angiogenesis Inhibitors | |
dc.subject | Vascular Endothelial Growth Factors | |
dc.subject | Neoplasm Proteins | |
dc.subject | Antineoplastic Agents | |
dc.subject | Antibodies, Monoclonal | |
dc.subject | Disease-Free Survival | |
dc.subject | Retrospective Studies | |
dc.subject | Single-Blind Method | |
dc.subject | Adult | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Multicenter Studies as Topic | |
dc.subject | Randomized Controlled Trials as Topic | |
dc.subject | Clinical Trials, Phase III as Topic | |
dc.subject | Kaplan-Meier Estimate | |
dc.subject | Antibodies, Monoclonal, Humanized | |
dc.subject | Biomarkers, Tumor | |
dc.title | Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-08-16 | |
rioxxterms.versionofrecord | 10.1038/bjc.2016.293 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-sa/4.0 | |
rioxxterms.licenseref.startdate | 2016-10 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | British journal of cancer | |
pubs.issue | 8 | |
pubs.notes | 12 months | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 115 | |
pubs.embargo.terms | 12 months | |
dc.contributor.icrauthor | Chau, Ian | |